We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
LabCorp's (LH) Q4 Earnings and Revenues Surpass Estimates
Read MoreHide Full Article
Laboratory Corporation of America Holdings (LH - Free Report) , or LabCorp, reported fourth-quarter 2018 adjusted earnings per share (EPS) of $2.52, up 11% from the year-ago quarter. The bottom line surpassed the Zacks Consensus Estimate by 1.6%.
On a reported basis, net earnings came in at $1.56 per share as compared with $6.63 a year ago.
Adjusted EPS in 2018 came in at $11.02, up 19.8% year over year. The figure also surpassed the Zacks Consensus Estimate of $11 by a slight margin.
Revenues in the quarter under review increased 1.6% year over year to $2.79 billion. The year-over-year rise was backed by 0.7% growth from acquisitions and organic growth of 2.9%, partially offset by a 1.6% negative impact from the disposition of businesses and a 40-basis point (bps) impact of foreign currency translation. The top line beat the Zacks Consensus Estimate by 0.2%.
Laboratory Corporation of America Holdings Price, Consensus and EPS Surprise
Revenues in 2018 came in at $11.33 billion, up 9.9% year over year. The figure was in line with the Zacks Consensus Estimate.
Quarter Under Review
LabCorp reports under two operating segments: LabCorp Diagnostics and Covance Drug Development.
In the fourth quarter, LabCorp Diagnostics reported revenues of $1.69 billion, a 2.8% drop year over year. While revenues were fueled by tuck-in acquisitions, a favorable mix and organic volume (measured by requisitions), this was offset by the negative impact from the disposition of businesses and the implementation of the Protecting Access to Medicare Act (PAMA). In addition, foreign currency translation reduced revenue by approximately 0.2%.
Excluding the disposition of businesses, the company reported a 0.3% rise in total volume (measured by requisition) and a 0.4% decline in revenue per requisition in the quarter under review.
Covance Drug Development reported a 9.6% rise in revenues to $1.10 billion in the fourth quarter. The upside was primarily driven by acquisitions and organic growth, partially offset by the adverse impact of foreign currency translation of nearly 90 bps.
Gross margin deteriorated 210 bps to 27.7% in the reported quarter. Adjusted operating income was down 6.1% year over year to $375.5 million. Also, adjusted operating margin contracted 110 bps from the year-ago quarter to 13.5%.
LabCorp exited 2018 with cash and cash equivalents of $426.8 million compared with $316.6 million at the end of 2017. In 2018, operating cash flow was $1.31 billion, down from $1.50 billion in the year-ago period. Free cash flow came in at $925.6 million in this period, down from $1.19 billion a year ago.
During the quarter under discussion, the company returned $400 million to shareholders via share repurchases. LabCorp informed that the company’s existing share repurchase plan has been replaced with a new plan authorizing repurchase of up to $1.25 billion.
Outlook
LabCorp has provided its 2019 guidance.
Revenue growth is expected in the band of 0.5-2.5% from 2018. This includes the adverse impact from the disposition of businesses of around 1% and foreign currency translation of roughly 0.4%. The Zacks Consensus Estimate for current-year revenues is pegged at $11.51 billion.
Adjusted EPS for 2019 is projected in the range of $11 to $11.40. The consensus mark of $11.21 for the metric is within the guided range.
Free cash flow is projected in the band of $950 million-$1.05 billion.
Our Take
LabCorp exited the fourth quarter on a promising note. While increasing acquisitions and a favorable mix positively contributed to LabCorp’s Diagnostics business in the quarter, the disposition of certain businesses and the implementation of PAMA dented growth.
Covance Drug Development, however, reported sturdy growth. The strength primarily came from acquisitions and robust organic growth. Nevertheless, adverse currency translation impacted the top line.
Zacks Rank & Key Picks
LabCorp carries a Zacks Rank #4 (Sell).
Some better-ranked MedTech stocks that posted solid quarterly results are Varian Medical Systems , AngioDynamics (ANGO - Free Report) and CONMED Corporation (CNMD - Free Report) .
Varian reported fiscal first-quarter adjusted EPS of $1.06, in line with the Zacks Consensus Estimate. Revenues of $741 million outpaced the consensus mark of $717.9 million. The stock has a Zacks Rank #2 (Buy).
AngioDynamics’ fiscal second-quarter adjusted EPS of 22 cents exceeded the Zacks Consensus Estimate by a penny. Revenues totaled $91.5 million, which surpassed the consensus estimate by 2.9%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
CONMED delivered fourth-quarter adjusted EPS of 73 cents, in line with the Zacks Consensus Estimate. Revenues of $242.4 million beat the Zacks Consensus Estimate of $229.2 million. The stock carries a Zacks Rank of 2.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
Image: Bigstock
LabCorp's (LH) Q4 Earnings and Revenues Surpass Estimates
Laboratory Corporation of America Holdings (LH - Free Report) , or LabCorp, reported fourth-quarter 2018 adjusted earnings per share (EPS) of $2.52, up 11% from the year-ago quarter. The bottom line surpassed the Zacks Consensus Estimate by 1.6%.
On a reported basis, net earnings came in at $1.56 per share as compared with $6.63 a year ago.
Adjusted EPS in 2018 came in at $11.02, up 19.8% year over year. The figure also surpassed the Zacks Consensus Estimate of $11 by a slight margin.
Revenues in the quarter under review increased 1.6% year over year to $2.79 billion. The year-over-year rise was backed by 0.7% growth from acquisitions and organic growth of 2.9%, partially offset by a 1.6% negative impact from the disposition of businesses and a 40-basis point (bps) impact of foreign currency translation. The top line beat the Zacks Consensus Estimate by 0.2%.
Laboratory Corporation of America Holdings Price, Consensus and EPS Surprise
Laboratory Corporation of America Holdings Price, Consensus and EPS Surprise | Laboratory Corporation of America Holdings Quote
Revenues in 2018 came in at $11.33 billion, up 9.9% year over year. The figure was in line with the Zacks Consensus Estimate.
Quarter Under Review
LabCorp reports under two operating segments: LabCorp Diagnostics and Covance Drug Development.
In the fourth quarter, LabCorp Diagnostics reported revenues of $1.69 billion, a 2.8% drop year over year. While revenues were fueled by tuck-in acquisitions, a favorable mix and organic volume (measured by requisitions), this was offset by the negative impact from the disposition of businesses and the implementation of the Protecting Access to Medicare Act (PAMA). In addition, foreign currency translation reduced revenue by approximately 0.2%.
Excluding the disposition of businesses, the company reported a 0.3% rise in total volume (measured by requisition) and a 0.4% decline in revenue per requisition in the quarter under review.
Covance Drug Development reported a 9.6% rise in revenues to $1.10 billion in the fourth quarter. The upside was primarily driven by acquisitions and organic growth, partially offset by the adverse impact of foreign currency translation of nearly 90 bps.
Gross margin deteriorated 210 bps to 27.7% in the reported quarter. Adjusted operating income was down 6.1% year over year to $375.5 million. Also, adjusted operating margin contracted 110 bps from the year-ago quarter to 13.5%.
LabCorp exited 2018 with cash and cash equivalents of $426.8 million compared with $316.6 million at the end of 2017. In 2018, operating cash flow was $1.31 billion, down from $1.50 billion in the year-ago period. Free cash flow came in at $925.6 million in this period, down from $1.19 billion a year ago.
During the quarter under discussion, the company returned $400 million to shareholders via share repurchases. LabCorp informed that the company’s existing share repurchase plan has been replaced with a new plan authorizing repurchase of up to $1.25 billion.
Outlook
LabCorp has provided its 2019 guidance.
Revenue growth is expected in the band of 0.5-2.5% from 2018. This includes the adverse impact from the disposition of businesses of around 1% and foreign currency translation of roughly 0.4%. The Zacks Consensus Estimate for current-year revenues is pegged at $11.51 billion.
Adjusted EPS for 2019 is projected in the range of $11 to $11.40. The consensus mark of $11.21 for the metric is within the guided range.
Free cash flow is projected in the band of $950 million-$1.05 billion.
Our Take
LabCorp exited the fourth quarter on a promising note. While increasing acquisitions and a favorable mix positively contributed to LabCorp’s Diagnostics business in the quarter, the disposition of certain businesses and the implementation of PAMA dented growth.
Covance Drug Development, however, reported sturdy growth. The strength primarily came from acquisitions and robust organic growth. Nevertheless, adverse currency translation impacted the top line.
Zacks Rank & Key Picks
LabCorp carries a Zacks Rank #4 (Sell).
Some better-ranked MedTech stocks that posted solid quarterly results are Varian Medical Systems , AngioDynamics (ANGO - Free Report) and CONMED Corporation (CNMD - Free Report) .
Varian reported fiscal first-quarter adjusted EPS of $1.06, in line with the Zacks Consensus Estimate. Revenues of $741 million outpaced the consensus mark of $717.9 million. The stock has a Zacks Rank #2 (Buy).
AngioDynamics’ fiscal second-quarter adjusted EPS of 22 cents exceeded the Zacks Consensus Estimate by a penny. Revenues totaled $91.5 million, which surpassed the consensus estimate by 2.9%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
CONMED delivered fourth-quarter adjusted EPS of 73 cents, in line with the Zacks Consensus Estimate. Revenues of $242.4 million beat the Zacks Consensus Estimate of $229.2 million. The stock carries a Zacks Rank of 2.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>